Group 1 - The company, Kangzheng Pharmaceutical, has signed a distribution agreement with Novartis Pharma Services AG for the exclusive import, distribution, sales, and promotion rights of two ophthalmic products in mainland China [1][2] - The agreement covers the products Ranibizumab Injection (trade name: 诺适得®) and Brolucizumab Injection (trade name: 倍优适®) for a duration of five years [1] - Novartis will continue to be responsible for the production and supply of these products [1] Group 2 - This collaboration is expected to enhance the competitiveness of Kangzheng Weisheng, the company's ophthalmology division, in the field of eye diseases [2] - The addition of these products will synergize with existing offerings, including the exclusive drug and medical device currently available, thereby strengthening the academic brand competitiveness in ophthalmology [2] - The professional ophthalmology team at Kangzheng Weisheng will integrate market channels and academic resources, which is anticipated to have a positive impact on the company's overall performance [2]
康哲药业(00867.HK)与诺华签订眼科药物诺适得®与倍优适®经销协议